In a groundbreaking study led by the Duncan Neurological Research Institute (Duncan NRI) at Texas Children’s Hospital and Baylor College of Medicine, scientists have made significant strides toward unraveling the early molecular mechanisms underlying Rett syndrome, a rare and severe neurological disorder primarily affecting girls. By employing advanced single-nucleus RNA sequencing techniques on genetically modified mice that model the human disease, the research team identified key gene expression disruptions and pinpointed specific cell types vulnerable at the earliest stages of symptom development. These insights are crucial, not only for understanding the pathogenesis of Rett syndrome but also for opening potential therapeutic avenues aimed at halting disease progression before debilitating symptoms manifest.
Rett syndrome is characterized by an almost normal development in infancy followed by a rapid regression of motor skills, speech, and social interaction typically occurring between 6 to 18 months of age. The disorder is rooted in mutations of the MECP2 gene, which encodes the protein methyl-CpG-binding protein 2. This protein plays an indispensable role in regulating gene expression by modulating the activity of thousands of downstream genes in brain cells. Mutations severely disrupt this regulatory capacity, leading to profound neurological dysfunction. One of the complexities of studying Rett syndrome lies in its distinctive genetic mosaicism in females, acquired due to the X-linked nature of the MECP2 gene. Female cells randomly inactivate one X chromosome, resulting in a brain that contains a mixture of cells expressing either the normal or mutant MECP2 gene, which interact in complex and dynamic ways.
The research team, led by Dr. Huda Zoghbi and colleagues including co-first authors Dr. Ashley Anderson and Yan Li, focused their investigation on the hippocampus—a brain region essential for memory and learning and known to be affected in the early phases of Rett syndrome. By physically separating cells expressing the healthy MECP2 gene from those with the mutated form prior to analysis, the investigators were able to conduct highly precise measurements of gene activity. They applied bulk RNA sequencing to capture overall tissue gene expression while complementary single-nucleus RNA sequencing provided a high-resolution view at the level of individual cells. This dual approach provided unprecedented insight into how the mosaic cellular environment contributes to disease pathology.
Initial analyses of bulk hippocampal tissue in female mutant mice uncovered only subtle gene expression changes, a finding that belied the severity of cellular dysfunction. However, the power of single-nucleus RNA sequencing revealed major disruptions within specific cell populations that had been obscured in bulk analyses by the heterogeneity of the tissue sample. Mutant MECP2 cells displayed pronounced gene dysregulation, affecting pathways crucial for synaptic function and intercellular communication—a finding that underscores the selective vulnerability of certain neuronal subtypes early in disease progression. Importantly, these cellular-level disruptions were consistent across male and female mice, despite differences in disease severity, leading to the identification of a set of 12 core genes that represent an early molecular signature of Rett syndrome.
This core set of dysregulated genes involves many that are directly implicated in synaptic transmission and plasticity, hinting that interception of synapse dysfunction could provide a strategic point for therapeutic intervention. The study also illuminated unexpected non-cell-autonomous effects in the brain: even genetically normal MECP2-positive cells showed altered gene expression profiles due to their proximity to mutant cells. These findings reflect intricate cellular interactions within the brain’s microenvironment, potentially explaining the widespread neurological impairments observed clinically, despite a substantial proportion of cells having functional MECP2.
Strikingly, the research identified a novel contribution of trilaminar interneurons—neurons that coordinate communication across different layers of the hippocampus—which exhibited particularly severe gene expression abnormalities linked to MECP2 mutations. This previously unrecognized vulnerability raises important questions about how disruptions in inhibitory circuits may exacerbate the network-wide dysfunction characteristic of Rett syndrome. Targeting these interneurons might represent a promising direction for future research and drug development.
Dr. Zoghbi emphasizes the transformative potential of these findings, noting that delineating the earliest molecular and cellular aberrations offers critical biomarkers for tracking therapeutic efficacy. Interventions designed to protect the most sensitive cell types or rectify the earliest genetic disruptions stand to alter the devastating natural history of Rett syndrome. Furthermore, this work extends beyond Rett syndrome itself—it carries profound implications for understanding mosaicism and cell type-specific vulnerabilities in other genetic neurological disorders.
This study was made possible by significant technical advances, including the unprecedented physical isolation of MECP2-positive and MECP2-negative cells, enabling a precise dissection of their distinct transcriptomic landscapes. Combined with powerful single-nucleus sequencing methodologies, this approach sets a new benchmark for dissecting cellular heterogeneity in brain disorders. The collaborative effort, supported by grants from the National Institute of Neurological Disorders and Stroke and the Howard Hughes Medical Institute, demonstrates the critical role of interdisciplinary and multimodal research in conquering complex neurogenetic diseases.
As clinical scientists and molecular biologists continue to deepen our understanding of Rett syndrome’s early pathophysiology, these findings offer renewed hope. The early molecular signatures and cell type-specific vulnerabilities identified here provide a roadmap for future drug targets and biomarker development. They mark a promising step toward precision medicine approaches that could one day stop Rett syndrome in its tracks before irreversible brain dysfunction sets in—transforming diagnosis, treatment, and ultimately, the lives of affected individuals and their families.
This study not only sheds light on the fundamental biology of Rett syndrome but also enriches the broader field of neuroscience by illustrating how mosaicism influences brain circuits, gene regulation, and cellular interactions. The Duncan NRI team’s discovery emphasizes that untangling these complex relationships at the single-cell level is essential for truly understanding and intervening in neurodevelopmental disorders. Their pioneering work, published in Science Advances, heralds a new era of neurogenetic research driven by high-resolution, cell-specific investigation.
Subject of Research: Molecular and cellular mechanisms underlying early gene expression changes and cell type vulnerabilities in Rett syndrome
Article Title: Single-nucleus profiling reveals a core disease signature and cell type–specific vulnerabilities in early Rett syndrome
News Publication Date: June 10, 2026
Web References:
Science Advances Journal
DOI: 10.5281/zenodo.18462624
Keywords: Clinical neuroscience, Genetics, Molecular biology, Pediatrics, Gene expression, Developmental disorders
Tags: Duncan Neurological Research Institute studiesearly gene expression changes in Rett syndromeearly intervention strategies in Rett syndromegenetic mouse models of Rett syndromeimpact of MECP2 on brain gene regulationMECP2 gene mutations and neurological disordersneurological disorder progression preventionpre-symptomatic biomarkers for Rett syndromeRett syndrome early molecular mechanismssingle-nucleus RNA sequencing in neurological researchtherapeutic targets for Rett syndromevulnerable brain cell types in Rett syndrome
